BioCentury
ARTICLE | Clinical News

NU1618: Phase IIa data

June 21, 2010 7:00 AM UTC

Top-line data from a double-blind, cross-over Phase IIa trial in 20 gout patients with hyperuricemia showed that high-dose NU1618 met the primary endpoint of significantly reducing sUA levels from baseline vs. 400 mg daily allopurinol (49% vs. 38%, p value not disclosed). On secondary endpoints, a significantly greater proportion of patients receiving high-dose NU1618 achieved a reduction in sUA levels to <4 mg/dL vs. 400 mg allopurinol (61% vs. 11%, p=0.0027). Patients received low- or high-dose NU1618, 300 mg/day tranilast, or 300 or 400 mg/day allopurinol. Nuon said the study was designed to focus on high-dose NU1618 in comparison to 400 mg allopurinol and that comparisons between other arms of the trial were exploratory endpoints that will be presented at an upcoming medical meeting. All treatment arms were well tolerated. ...